Treximet
Treximet (formerly known as Trexima) is a medication manufactured by GlaxoSmithKline and POZEN Pharmaceutical Development Company for the treatment of migraines.[1]
Contents |
[edit] Active ingredients
It combines sumatriptan (as the succinate), a selective 5-hydroxytryptamine1 (5-HT1) receptor subtype agonist and naproxen sodium, a member of the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs).[2]
This drug has a unique RT formulation that allows for the rapid disintegration of the sumatriptan, but it does not affect the disintegration of the naproxen sodium component.
It targets nerves and blood vessels believed to trigger a migraine and relieves the inflammation that can cause migraine pain.
Available in 25 mg, 50 mg and 100 mg strengths tablets. In clinical trials, Treximet provided a significantly greater percentage of patients migraine pain relief at two hours compared to sumatriptan 85 mg or naproxen sodium 500 mg alone. In addition, Treximet provided more patients sustained migraine pain relief from two to 24 hours compared to the individual components.
[edit] Clinical trials
During clinical trials Treximet performed better than placebo and better than the single ingredients by themselves. Treximet provided lasting relief in some cases for 24 hours. Treximet was also effective in reducing symptoms of migraines, such as nausea and sensitivity to light or sound.
[edit] Side effects
Some of the listed side effects include dizziness, nausea, sleepiness, dry mouth, pain in neck, throat or jaw, numbness or tingling.[3]
[edit] Increased risks
Treximet may cause increased risks of clotting, heart attack and stroke. Treximet may also increase risks of gastrointestinal problems and ulcers.
